These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21085001)

  • 1. Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT substudy.
    Patti G; Chello M; Pasceri V; Colonna D; Colonna G; Pepe LL; Montinaro A; Covino E; Di Sciascio G
    J Cardiovasc Med (Hagerstown); 2011 Mar; 12(3):151-6. PubMed ID: 21085001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.
    Di Sciascio G; Patti G; Pasceri V; Colonna G; Mangiacapra F; Montinaro A;
    Eur Heart J; 2010 Jun; 31(11):1337-43. PubMed ID: 20363764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study.
    Patti G; Bárczi G; Orlic D; Mangiacapra F; Colonna G; Pasceri V; Barbato E; Merkely B; Edes I; Ostojic M; Wijns W; Di Sciascio G
    J Am Coll Cardiol; 2011 Oct; 58(15):1592-9. PubMed ID: 21958886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.
    Di Sciascio G; Patti G; Pasceri V; Gatto L; Colonna G; Montinaro A;
    J Am Coll Cardiol; 2010 Aug; 56(7):550-7. PubMed ID: 20688209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.
    Patti G; Colonna G; Pasceri V; Pepe LL; Montinaro A; Di Sciascio G
    Circulation; 2005 Apr; 111(16):2099-106. PubMed ID: 15750189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
    JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
    Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study.
    Patti G; Grieco D; Dicuonzo G; Pasceri V; Nusca A; Di Sciascio G
    J Am Coll Cardiol; 2011 Feb; 57(7):771-8. PubMed ID: 21310311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
    Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
    Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study.
    Mangiacapra F; Patti G; Barbato E; Orlic D; Peace AJ; D'Ambrosio A; Ostojic M; Wijns W; Di Sciascio G
    Int J Cardiol; 2012 Oct; 160(3):213-4. PubMed ID: 22727961
    [No Abstract]   [Full Text] [Related]  

  • 11. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
    Abuzahra M; Pillai M; Caldera A; Hartley WB; Gonzalez R; Bobek J; Dokainish H; Lakkis N
    Am J Cardiol; 2008 Aug; 102(4):401-3. PubMed ID: 18678295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
    Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
    J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
    Mangiacapra F; Muller O; Ntalianis A; Trana C; Heyndrickx GR; Bartunek J; Vanderheyden M; Wijns W; De Bruyne B; Barbato E
    Am J Cardiol; 2010 Nov; 106(9):1208-11. PubMed ID: 21029814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial.
    Nguyen TA; Lordkipanidzé M; Diodati JG; Palisaitis DA; Schampaert E; Turgeon J; Pharand C
    J Interv Cardiol; 2009 Aug; 22(4):368-77. PubMed ID: 19689661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
    Chen WH; Lee PY; Ng W; Tse HF; Lau CP
    J Am Coll Cardiol; 2004 Mar; 43(6):1122-6. PubMed ID: 15028378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.